<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Gynecol Obstet</journal-id><journal-title>Archives of Gynecology and Obstetrics</journal-title><issn pub-type="ppub">0932-0067</issn><issn pub-type="epub">1432-0711</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16957911</article-id><article-id pub-id-type="pmc">1705528</article-id><article-id pub-id-type="publisher-id">234</article-id><article-id pub-id-type="doi">10.1007/s00404-006-0234-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Single-day therapy: an expert opinion on a recent development for the episodic treatment of recurrent genital herpes</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Tyring</surname><given-names>Stephen</given-names></name><address><phone>+1-281-3332288</phone><fax>+1-281-3354605</fax><email>styring@ccstexas.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Richwald</surname><given-names>Gary</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hamed</surname><given-names>Kamal</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Department of Dermatology, Microbiology and Molecular Genetics and Internal Medicine, University of Texas Health Science Center, 2060 Space Park Drive, Suite 200, Houston, TX 77058 USA </aff><aff id="Aff2"><label>2</label>Los Angeles, CA USA </aff><aff id="Aff3"><label>3</label>Infectious Diseases, Transplantation and Immunology Unit, Novartis, East Hanover, NJ USA </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>9</month><year>2006</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2007</year></pub-date><volume>275</volume><issue>1</issue><fpage>1</fpage><lpage>3</lpage><history><date date-type="received"><day>21</day><month>7</month><year>2006</year></date><date date-type="accepted"><day>7</day><month>8</month><year>2006</year></date></history><permissions><copyright-statement>© Springer-Verlag 2006</copyright-statement></permissions><abstract><p><offsets xml_i="2559" xml_f="3392" txt_i="11" txt_f="844">One common method for treating recurrent genital herpes outbreaks is 3–5 day episodic therapy with nucleoside analogues. However, since maximum viral replication occurs within 24 h after the onset of symptoms, short-term patient-initiated episodic therapy started at prodromal onset or at the first appearance of lesions in patients without a prodrome may represent an important option. In a recent randomized trial, single-day famciclovir treatment decreased lesion healing time and the duration of pain and other symptoms by approximately 2 days compared to placebo, and prevented progression to a full outbreak in almost one in four patients. Because single-day treatment is more convenient than traditional therapies, it may lead to improved patient compliance and better overall management of recurrent genital herpes outbreaks.</offsets></p></abstract><kwd-group><title>Keywords</title><kwd>Single-day famciclovir</kwd><kwd>Genital herpes</kwd><kwd>Patient-initiated episodic therapy</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer-Verlag 2006</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title><offsets xml_i="3790" xml_f="3802" txt_i="852" txt_f="864">Introduction</offsets></title><p><offsets xml_i="3813" xml_f="4072" txt_i="865" txt_f="1124">Recurrent genital herpes outbreaks are predominantly caused by herpes simplex virus type 2 (HSV-2), although the incidence of genital herpes caused by herpes simplex virus type 1 (HSV-1) is rising due to changing attitudes about oral-genital sexual behavior [</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="4105" xml_f="4107" txt_i="1124" txt_f="1126">10</offsets></xref><offsets xml_i="4114" xml_f="4198" txt_i="1126" txt_f="1210">]. Approximately one in four adults in the United States is seropositive for HSV-2 [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="4230" xml_f="4231" txt_i="1210" txt_f="1211">7</offsets></xref><offsets xml_i="4238" xml_f="4497" txt_i="1211" txt_f="1470">], an incurable infection that initially enters the body through mucous membranes or abraded skin. Once primary infection has occurred, the virus remains dormant in the dorsal root ganglia, where it can reactivate to cause uncomfortable, recurrent outbreaks [</offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="4530" xml_f="4532" txt_i="1470" txt_f="1472">20</offsets></xref><offsets xml_i="4539" xml_f="4541" txt_i="1472" txt_f="1474">].</offsets></p><p><offsets xml_i="4548" xml_f="4613" txt_i="1475" txt_f="1540">HSV-2 infection is somewhat more prevalent in women than in men [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="4645" xml_f="4646" txt_i="1540" txt_f="1541">7</offsets></xref><offsets xml_i="4653" xml_f="4929" txt_i="1541" txt_f="1817">], and can have a profound psychological impact as well as physical repercussions, resulting in a decrease in measures of quality of life. The fear of spreading the infection can result in lowered self-esteem or sexual desire and, less commonly, social phobia and depression [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="4961" xml_f="4962" txt_i="1817" txt_f="1818">6</offsets></xref><offsets xml_i="4969" xml_f="5099" txt_i="1818" txt_f="1948">]. In addition, patients with genital herpes have a significantly increased risk of acquiring human immunodeficiency virus (HIV) [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="5131" xml_f="5132" txt_i="1948" txt_f="1949">8</offsets></xref><offsets xml_i="5139" xml_f="5141" txt_i="1949" txt_f="1951">].</offsets></p></sec><sec id="Sec2"><title><offsets xml_i="5173" xml_f="5210" txt_i="1953" txt_f="1990">Episodic treatment for genital herpes</offsets></title><p><offsets xml_i="5221" xml_f="5604" txt_i="1991" txt_f="2374">Although there is no cure for HSV-2 infection, patients have two treatment options: treating outbreaks as they occur (episodic therapy), or attempting to prevent future outbreaks (suppressive therapy). Suppression with daily oral antivirals may be most appropriate for patients with frequent or uncomfortable recurrences and to reduce genital herpes transmission to sexual partners [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="5636" xml_f="5637" txt_i="2374" txt_f="2375">4</offsets></xref><offsets xml_i="5644" xml_f="5788" txt_i="2375" txt_f="2519">]. Although suppressive therapy is effective, one quarter to one half of patients on suppressive therapy have at least one recurrence per year [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="5821" xml_f="5822" txt_i="2519" txt_f="2520">5</offsets></xref><offsets xml_i="5829" xml_f="5831" txt_i="2520" txt_f="2522">, </offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="5863" xml_f="5865" txt_i="2522" txt_f="2524">14</offsets></xref><offsets xml_i="5872" xml_f="5874" txt_i="2524" txt_f="2526">].</offsets></p><p><offsets xml_i="5881" xml_f="6313" txt_i="2527" txt_f="2959">Although episodic treatment has not been proven to reduce the risk of transmission, it still remains an important option for patients who do not want to take daily suppressive therapy, are not concerned about the frequency of recurrences, or are not sexually active. The best method for administering episodic therapy is to make medication readily available to patients to self-administer at the first onset of symptoms or lesions [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="6346" xml_f="6348" txt_i="2959" txt_f="2961">16</offsets></xref><offsets xml_i="6355" xml_f="6490" txt_i="2961" txt_f="3096">]. This type of patient-initiated episodic therapy has been successfully used in previous clinical trials of recurrent genital herpes [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="6523" xml_f="6525" txt_i="3096" txt_f="3098">13</offsets></xref><offsets xml_i="6532" xml_f="6534" txt_i="3098" txt_f="3100">, </offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="6567" xml_f="6569" txt_i="3100" txt_f="3102">15</offsets></xref><offsets xml_i="6576" xml_f="6710" txt_i="3102" txt_f="3236">]. The ability to treat recurrences sooner may also help decrease the duration of an outbreak or halt progression to a full outbreak [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="6743" xml_f="6744" txt_i="3236" txt_f="3237">9</offsets></xref><offsets xml_i="6751" xml_f="6753" txt_i="3237" txt_f="3239">, </offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="6786" xml_f="6788" txt_i="3239" txt_f="3241">13</offsets></xref><offsets xml_i="6795" xml_f="6797" txt_i="3241" txt_f="3243">, </offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="6830" xml_f="6832" txt_i="3243" txt_f="3245">15</offsets></xref><offsets xml_i="6839" xml_f="6841" txt_i="3245" txt_f="3247">, </offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="6873" xml_f="6875" txt_i="3247" txt_f="3249">19</offsets></xref><offsets xml_i="6882" xml_f="7074" txt_i="3249" txt_f="3441">]. This expert opinion will examine the results from a recently published clinical trial about patient-initiated, single-day oral antiviral therapy (famciclovir) for recurrent genital herpes [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="7106" xml_f="7107" txt_i="3441" txt_f="3442">2</offsets></xref><offsets xml_i="7114" xml_f="7186" txt_i="3442" txt_f="3514">] and compare its efficacy with data from currently available therapies.</offsets></p></sec><sec id="Sec3"><title><offsets xml_i="7218" xml_f="7276" txt_i="3516" txt_f="3574">Treatment of recurrent genital herpes with oral antivirals</offsets></title><p><offsets xml_i="7287" xml_f="7503" txt_i="3575" txt_f="3791">Patients with recurrent episodes of genital herpes often experience such prodromal symptoms as itching, tingling, burning, and pain, with papules and vesicles typically forming 12–24 h after onset of these symptoms [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="7535" xml_f="7536" txt_i="3791" txt_f="3792">3</offsets></xref><offsets xml_i="7543" xml_f="7664" txt_i="3792" txt_f="3913">]. Maximum HSV-2 concentration and lesion pain usually occur within the first 24 h of onset of these prodromal symptoms [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="7696" xml_f="7697" txt_i="3913" txt_f="3914">3</offsets></xref><offsets xml_i="7704" xml_f="7795" txt_i="3914" txt_f="4005">]. Under the assumption that one can extrapolate from the pathogenesis of herpes labialis [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="7828" xml_f="7830" txt_i="4005" txt_f="4007">17</offsets></xref><offsets xml_i="7837" xml_f="8043" txt_i="4007" txt_f="4213">], it is thought that the most effective way to treat recurrent genital herpes with antiviral therapy would be within the first 24 h after the onset of clinical symptoms, when viral replication is highest [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="8076" xml_f="8078" txt_i="4213" txt_f="4215">16</offsets></xref><offsets xml_i="8085" xml_f="8439" txt_i="4215" txt_f="4569">]. Oral antivirals, acting as nucleoside analogues enter infected cells and bind to viral thymidine kinase, resulting in their phosphorylation. After the antivirals are further phosphorylated by cellular enzymes, they compete with nucleosides to bind to the viral DNA polymerase, resulting in polymerase inactivation and a decrease in viral replication [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="8472" xml_f="8474" txt_i="4569" txt_f="4571">16</offsets></xref><offsets xml_i="8481" xml_f="8483" txt_i="4571" txt_f="4573">].</offsets></p><p><offsets xml_i="8490" xml_f="8638" txt_i="4574" txt_f="4722">Although topical acyclovir was initially used to treat recurrent genital herpes, it has since been proven ineffective and is no longer recommended [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="8671" xml_f="8672" txt_i="4722" txt_f="4723">1</offsets></xref><offsets xml_i="8679" xml_f="8681" txt_i="4723" txt_f="4725">, </offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="8713" xml_f="8715" txt_i="4725" txt_f="4727">12</offsets></xref><offsets xml_i="8722" xml_f="8942" txt_i="4727" txt_f="4947">]. Today, the most commonly prescribed drugs are the oral antivirals acyclovir, valacyclovir, and famciclovir. Acyclovir is approved for 5-day episodic treatment, although a 2-day regimen has been shown to be effective [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="8975" xml_f="8977" txt_i="4947" txt_f="4949">13</offsets></xref><offsets xml_i="8984" xml_f="8986" txt_i="4949" txt_f="4951">, </offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="9019" xml_f="9021" txt_i="4951" txt_f="4953">19</offsets></xref><offsets xml_i="9028" xml_f="9249" txt_i="4953" txt_f="5174">]. Acyclovir is effective, but its poor bioavailability requires more frequent dosing. Valacyclovir, a prodrug of acyclovir, has a higher bioavailability than acyclovir and has been approved for 3-day episodic treatment [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="9282" xml_f="9283" txt_i="5174" txt_f="5175">9</offsets></xref><offsets xml_i="9290" xml_f="9292" txt_i="5175" txt_f="5177">, </offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="9324" xml_f="9326" txt_i="5177" txt_f="5179">14</offsets></xref><offsets xml_i="9333" xml_f="9419" txt_i="5179" txt_f="5265">]. Famciclovir, a prodrug of penciclovir, is currently indicated for 5-day treatment [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="9452" xml_f="9454" txt_i="5265" txt_f="5267">11</offsets></xref><offsets xml_i="9461" xml_f="9463" txt_i="5267" txt_f="5269">, </offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="9496" xml_f="9498" txt_i="5269" txt_f="5271">15</offsets></xref><offsets xml_i="9505" xml_f="9723" txt_i="5271" txt_f="5489">]. The high bioavailability of famciclovir (77%) and the rapid onset of viral replication in recurrent genital herpes suggested that this medication would be efficacious in an even shorter single-day treatment regimen.</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="9755" xml_f="9802" txt_i="5491" txt_f="5538">Data from single-day famciclovir clinical trial</offsets></title><p><offsets xml_i="9813" xml_f="9968" txt_i="5539" txt_f="5694">A clinical trial was performed to assess whether single-day famciclovir was effective in treating recurrent genital herpes in immunocompetent individuals [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="10000" xml_f="10001" txt_i="5694" txt_f="5695">2</offsets></xref><offsets xml_i="10008" xml_f="10847" txt_i="5695" txt_f="6534">]. The 329 study participants experiencing a recurrence of genital herpes were predominately female (71%) and 48% had had more than six recurrences in the preceding year. Participants were given a single day of famciclovir 1,000 mg bid or matching placebo and were instructed to take the medication within 6 h of the onset of prodromal symptoms and/or genital herpes lesions during their next recurrence. The trial results showed that a single-day regimen of famciclovir significantly decreased lesion-healing time and significantly reduced time to resolution of all symptoms by 2 days, as compared to placebo. Famciclovir also halted the progression to a full genital herpes outbreak in almost one in four patients. Adverse events were of mild-to-moderate intensity and were similar to the adverse events experienced by the placebo group.</offsets></p><p><offsets xml_i="10854" xml_f="11124" txt_i="6535" txt_f="6805">Although no head-to-head studies have been conducted between single-day famciclovir and other oral antivirals, patients who received single-day famciclovir experienced effects similar to those seen in previous clinical trials of traditional longer-term therapies (Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="11158" xml_f="11159" txt_i="6805" txt_f="6806">1</offsets></xref><offsets xml_i="11166" xml_f="11169" txt_i="6806" txt_f="6809">) [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="11202" xml_f="11203" txt_i="6809" txt_f="6810">2</offsets></xref><offsets xml_i="11210" xml_f="11212" txt_i="6810" txt_f="6812">, </offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="11245" xml_f="11246" txt_i="6812" txt_f="6813">9</offsets></xref><offsets xml_i="11253" xml_f="11255" txt_i="6813" txt_f="6815">, </offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="11288" xml_f="11290" txt_i="6815" txt_f="6817">13</offsets></xref><offsets xml_i="11297" xml_f="11299" txt_i="6817" txt_f="6819">, </offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="11331" xml_f="11333" txt_i="6819" txt_f="6821">15</offsets></xref><offsets xml_i="11340" xml_f="11342" txt_i="6821" txt_f="6823">, </offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="11374" xml_f="11376" txt_i="6823" txt_f="6825">18</offsets></xref><offsets xml_i="11383" xml_f="11385" txt_i="6825" txt_f="6827">, </offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="11418" xml_f="11420" txt_i="6827" txt_f="6829">19</offsets></xref><offsets xml_i="11427" xml_f="11647" txt_i="6829" txt_f="7049">]. Single-day therapy appears to inhibit viral replication enough to significantly reduce both symptoms and the tissue damage characteristic of a full outbreak, preventing progression to a full recurrence in some cases.
</offsets><table-wrap id="Tab1"><label><offsets xml_i="11676" xml_f="11683" txt_i="7049" txt_f="7056">Table 1</offsets></label><caption><p><offsets xml_i="11703" xml_f="11795" txt_i="7056" txt_f="7148">Effectiveness of oral antivirals in clinical trials of episodic treatment for genital herpes</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><offsets xml_i="11874" xml_f="11878" txt_i="7149" txt_f="7153">Drug</offsets></th><th align="left"><offsets xml_i="11900" xml_f="11917" txt_i="7153" txt_f="7170">Treatment regimen</offsets></th><th align="left"><offsets xml_i="11939" xml_f="11998" txt_i="7170" txt_f="7229">Median time (days) to lesion healing (treatment vs control)</offsets></th><th align="left"><offsets xml_i="12020" xml_f="12070" txt_i="7229" txt_f="7279">Percent of aborted episodes (treatment vs control)</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="12116" xml_f="12127" txt_i="7279" txt_f="7290">Acyclovir [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="12160" xml_f="12162" txt_i="7290" txt_f="7292">13</offsets></xref><offsets xml_i="12169" xml_f="12171" txt_i="7292" txt_f="7294">, </offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="12204" xml_f="12206" txt_i="7294" txt_f="7296">19</offsets></xref><offsets xml_i="12213" xml_f="12214" txt_i="7296" txt_f="7297">]</offsets></td><td align="left"><offsets xml_i="12236" xml_f="12270" txt_i="7298" txt_f="7332">800 mg tid × 2 days versus placebo</offsets><break></break><offsets xml_i="12285" xml_f="12329" txt_i="7332" txt_f="7376">200 mg 5 times daily × 5 days versus placebo</offsets></td><td align="left"><offsets xml_i="12351" xml_f="12367" txt_i="7377" txt_f="7393">4.0 versus 6.0 (</offsets><italic><offsets xml_i="12375" xml_f="12377" txt_i="7393" txt_f="7395">P </offsets></italic><offsets xml_i="12386" xml_f="12394" txt_i="7395" txt_f="7403">= .001) </offsets><break></break><offsets xml_i="12409" xml_f="12423" txt_i="7403" txt_f="7417">5.7 versus 7.2</offsets><sup><offsets xml_i="12428" xml_f="12430" txt_i="7417" txt_f="7419">a </offsets></sup><offsets xml_i="12436" xml_f="12437" txt_i="7419" txt_f="7420">(</offsets><italic><offsets xml_i="12445" xml_f="12447" txt_i="7420" txt_f="7422">P </offsets></italic><offsets xml_i="12456" xml_f="12463" txt_i="7422" txt_f="7429">≤ .001)</offsets></td><td align="left"><offsets xml_i="12485" xml_f="12504" txt_i="7430" txt_f="7449">27.0 versus 10.6% (</offsets><italic><offsets xml_i="12512" xml_f="12514" txt_i="7449" txt_f="7451">P </offsets></italic><offsets xml_i="12523" xml_f="12530" txt_i="7451" txt_f="7458">= .029)</offsets><break></break><offsets xml_i="12545" xml_f="12566" txt_i="7458" txt_f="7479">    Was not performed</offsets></td></tr><tr><td align="left"><offsets xml_i="12597" xml_f="12611" txt_i="7480" txt_f="7494">Valacyclovir [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="12643" xml_f="12644" txt_i="7494" txt_f="7495">9</offsets></xref><offsets xml_i="12651" xml_f="12653" txt_i="7495" txt_f="7497">, </offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="12686" xml_f="12688" txt_i="7497" txt_f="7499">18</offsets></xref><offsets xml_i="12695" xml_f="12696" txt_i="7499" txt_f="7500">]</offsets></td><td align="left"><offsets xml_i="12718" xml_f="12764" txt_i="7501" txt_f="7547">500 mg bid × 3 days versus 500 mg bid × 5 days</offsets><break></break><offsets xml_i="12779" xml_f="12862" txt_i="7547" txt_f="7630">1,000 mg bid × 5 days versus 200 mg acyclovir 5 times daily × 5 days versus placebo</offsets></td><td align="left"><offsets xml_i="12884" xml_f="12900" txt_i="7631" txt_f="7647">4.4 versus 4.7 (</offsets><italic><offsets xml_i="12908" xml_f="12910" txt_i="7647" txt_f="7649">P </offsets></italic><offsets xml_i="12919" xml_f="12924" txt_i="7649" txt_f="7654">= NS)</offsets><break></break><offsets xml_i="12939" xml_f="12966" txt_i="7654" txt_f="7681">4.8 versus 4.8 versus 6.0 (</offsets><italic><offsets xml_i="12974" xml_f="12976" txt_i="7681" txt_f="7683">P </offsets></italic><offsets xml_i="12985" xml_f="12995" txt_i="7683" txt_f="7690">&lt; .001)</offsets><sup><offsets xml_i="13000" xml_f="13001" txt_i="7690" txt_f="7691">b</offsets></sup></td><td align="left"><offsets xml_i="13029" xml_f="13048" txt_i="7692" txt_f="7711">25.4 versus 26.6% (</offsets><italic><offsets xml_i="13056" xml_f="13058" txt_i="7711" txt_f="7713">P </offsets></italic><offsets xml_i="13067" xml_f="13072" txt_i="7713" txt_f="7718">= NS)</offsets><break></break><offsets xml_i="13087" xml_f="13118" txt_i="7718" txt_f="7749">25.9 versus 24.8 versus 19.8% (</offsets><italic><offsets xml_i="13126" xml_f="13128" txt_i="7749" txt_f="7751">P </offsets></italic><offsets xml_i="13137" xml_f="13142" txt_i="7751" txt_f="7756">= NS)</offsets></td></tr><tr><td align="left"><offsets xml_i="13173" xml_f="13186" txt_i="7757" txt_f="7770">Famciclovir [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="13219" xml_f="13220" txt_i="7770" txt_f="7771">2</offsets></xref><offsets xml_i="13227" xml_f="13229" txt_i="7771" txt_f="7773">, </offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="13261" xml_f="13263" txt_i="7773" txt_f="7775">15</offsets></xref><offsets xml_i="13270" xml_f="13271" txt_i="7775" txt_f="7776">]</offsets></td><td align="left"><offsets xml_i="13293" xml_f="13328" txt_i="7777" txt_f="7812">1,000 mg bid × 1 day versus placebo</offsets><break></break><offsets xml_i="13343" xml_f="13377" txt_i="7812" txt_f="7846">125 mg bid × 5 days versus placebo</offsets></td><td align="left"><offsets xml_i="13399" xml_f="13415" txt_i="7847" txt_f="7863">4.3 versus 6.1 (</offsets><italic><offsets xml_i="13423" xml_f="13425" txt_i="7863" txt_f="7865">P </offsets></italic><offsets xml_i="13434" xml_f="13444" txt_i="7865" txt_f="7872">&lt; .001)</offsets><break></break><offsets xml_i="13459" xml_f="13475" txt_i="7872" txt_f="7888">3.8 versus 4.8 (</offsets><italic><offsets xml_i="13483" xml_f="13485" txt_i="7888" txt_f="7890">P </offsets></italic><offsets xml_i="13494" xml_f="13504" txt_i="7890" txt_f="7897">&lt; .001)</offsets></td><td align="left"><offsets xml_i="13526" xml_f="13545" txt_i="7898" txt_f="7917">23.3 versus 12.7% (</offsets><italic><offsets xml_i="13553" xml_f="13555" txt_i="7917" txt_f="7919">P </offsets></italic><offsets xml_i="13564" xml_f="13571" txt_i="7919" txt_f="7926">= .003)</offsets><break></break><offsets xml_i="13586" xml_f="13603" txt_i="7926" txt_f="7943">Was not performed</offsets></td></tr></tbody></table><table-wrap-foot><p><sup><offsets xml_i="13654" xml_f="13655" txt_i="7944" txt_f="7945">a</offsets></sup><offsets xml_i="13661" xml_f="13681" txt_i="7945" txt_f="7965">Mean time to healing</offsets></p><p><sup><offsets xml_i="13693" xml_f="13694" txt_i="7966" txt_f="7967">b</offsets></sup><italic><offsets xml_i="13708" xml_f="13709" txt_i="7967" txt_f="7968">P</offsets></italic><offsets xml_i="13718" xml_f="13801" txt_i="7968" txt_f="8051"> values correspond to both valacyclovir versus placebo and acyclovir versus placebo</offsets></p><p><offsets xml_i="13808" xml_f="13828" txt_i="8052" txt_f="8072">NS = Not significant</offsets></p></table-wrap-foot></table-wrap></p></sec><sec id="Sec5" sec-type="conclusion"><title><offsets xml_i="13917" xml_f="13927" txt_i="8075" txt_f="8085">Conclusion</offsets></title><p><offsets xml_i="13938" xml_f="14564" txt_i="8086" txt_f="8712">The rapid onset of viral replication in recurrent genital herpes suggests that a shorter course of therapy would be as efficacious as traditional treatments. Patient-initiated single-day therapy could prove helpful for obstetricians/gynecologists who treat patients with genital herpes, as it may provide a more convenient option for treating the disease, and could help to promote patient compliance. High bioavailability, ease of use, and the added benefit of preventing progression to a full genital herpes outbreak in some patients make famciclovir an excellent candidate for single-day patient-initiated episodic therapy.</offsets></p></sec></body><back><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="other">ACOG Committee on Practice Bulletins—Gynecology (2004) Obstet Gynecol 104(5 pt 1):1111–1118</citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname><given-names>FY</given-names></name><name><surname>Tyring</surname><given-names>S</given-names></name><name><surname>Mitoma-Diaz</surname><given-names>F</given-names></name><name><surname>Gross</surname><given-names>G</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Hamed</surname><given-names>K</given-names></name></person-group><article-title>Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double blind, placebo-controlled trial</article-title><source>Clin Infect Dis</source><year>2006</year><volume>42</volume><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1086/498521</pub-id></citation><citation citation-type="display-unstructured">Aoki FY, Tyring S, Mitoma-Diaz F, Gross G, Gao J, Hamed K (2006) Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double blind, placebo-controlled trial. Clin Infect Dis 42:8–13 <pub-id pub-id-type="pmid">16323085</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>ZA</given-names></name><name><surname>Kern</surname><given-names>ER</given-names></name><name><surname>Spruance</surname><given-names>SL</given-names></name><name><surname>Overall</surname><given-names>JC</given-names></name></person-group><article-title>Clinical and virologic course of herpes simplex genitalis</article-title><source>West J Med</source><year>1979</year><volume>130</volume><fpage>414</fpage><lpage>421</lpage></citation><citation citation-type="display-unstructured">Brown ZA, Kern ER, Spruance SL, Overall JC Jr (1979) Clinical and virologic course of herpes simplex genitalis. West J Med 130:414–421 <pub-id pub-id-type="pmid">229646</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corey</surname><given-names>L</given-names></name><name><surname>Wald</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Sacks</surname><given-names>SL</given-names></name><name><surname>Tyring</surname><given-names>SK</given-names></name><name><surname>Warren</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Once-daily valacyclovir to reduce the risk of transmission of genital herpes</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa035144</pub-id></citation><citation citation-type="display-unstructured">Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al (2004) Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 350:11–20 <pub-id pub-id-type="pmid">14702423</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Mitoma</surname><given-names>F</given-names></name><name><surname>Sibbald</surname><given-names>G</given-names></name><name><surname>Shafran</surname><given-names>SD</given-names></name><name><surname>Boon</surname><given-names>R</given-names></name><name><surname>Saltzman</surname><given-names>RL</given-names></name></person-group><article-title>Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial</article-title><source>JAMA</source><year>1998</year><volume>280</volume><fpage>887</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1001/jama.280.10.887</pub-id></citation><citation citation-type="display-unstructured">Diaz-Mitoma F, Sibbald G, Shafran SD, Boon R, Saltzman RL (1998) Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA 280:887–892 <pub-id pub-id-type="pmid">9739972</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drob</surname><given-names>S</given-names></name><name><surname>Loemer</surname><given-names>M</given-names></name><name><surname>Lifshutz</surname><given-names>H</given-names></name></person-group><article-title>Genital herpes: the psychological consequences</article-title><source>Br J Med Psychol</source><year>1985</year><volume>58</volume><issue>Pt 4</issue><fpage>307</fpage><lpage>315</lpage></citation><citation citation-type="display-unstructured">Drob S, Loemer M, Lifshutz H (1985) Genital herpes: the psychological consequences. Br J Med Psychol 58(Pt 4):307–315 <pub-id pub-id-type="pmid">4092013</pub-id></citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>DT</given-names></name><name><surname>McQuillan</surname><given-names>GM</given-names></name><name><surname>Johnson</surname><given-names>RE</given-names></name><etal></etal></person-group><article-title>Herpes simplex virus type 2 in the United States, 1976–1994</article-title><source>N Engl J Med</source><year>1997</year><volume>337</volume><fpage>1105</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1056/NEJM199710163371601</pub-id></citation><citation citation-type="display-unstructured">Fleming DT, McQuillan GM, Johnson RE, et al (1997) Herpes simplex virus type 2 in the United States, 1976–1994. N Engl J Med 337:1105–1111 <pub-id pub-id-type="pmid">9329932</pub-id></citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>EE</given-names></name><name><surname>Weiss</surname><given-names>HA</given-names></name><name><surname>Glynn</surname><given-names>JR</given-names></name><name><surname>Cross</surname><given-names>PL</given-names></name><name><surname>Whitworth</surname><given-names>JA</given-names></name><name><surname>Hayes</surname><given-names>RJ</given-names></name></person-group><article-title>Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies</article-title><source>AIDS</source><year>2006</year><volume>20</volume><fpage>73</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1097/01.aids.0000198081.09337.a7</pub-id></citation><citation citation-type="display-unstructured">Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:73–83 <pub-id pub-id-type="pmid">16327322</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leone</surname><given-names>PA</given-names></name><name><surname>Trottier</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>JM</given-names></name></person-group><article-title>Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment</article-title><source>Clin Infect Dis</source><year>2002</year><volume>34</volume><fpage>958</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1086/339326</pub-id></citation><citation citation-type="display-unstructured">Leone PA, Trottier S, Miller JM (2002) Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 34:958–962 <pub-id pub-id-type="pmid">11880962</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malkin</surname><given-names>JE</given-names></name></person-group><article-title>Epidemiology of genital herpes simplex virus infection in developed countries</article-title><source>Herpes</source><year>2004</year><volume>11</volume><issue>suppl 1</issue><fpage>2A</fpage><lpage>23A</lpage></citation><citation citation-type="display-unstructured">Malkin JE (2004) Epidemiology of genital herpes simplex virus infection in developed countries. Herpes 11(suppl 1):2A–23A <pub-id pub-id-type="pmid">15115626</pub-id></citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pue</surname><given-names>MA</given-names></name><name><surname>Benet</surname><given-names>MA</given-names></name></person-group><article-title>Pharmacokinetics of famciclovir in man</article-title><source>Antivir Chem Chemother</source><year>1993</year><volume>4</volume><issue>suppl 1</issue><fpage>47</fpage><lpage>55</lpage></citation><citation citation-type="display-unstructured">Pue MA, Benet MA (1993) Pharmacokinetics of famciclovir in man. Antivir Chem Chemother 4(suppl 1):47–55 </citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reichman</surname><given-names>RC</given-names></name><name><surname>Badger</surname><given-names>GJ</given-names></name><name><surname>Guinan</surname><given-names>ME</given-names></name><name><surname>Nahmias</surname><given-names>AJ</given-names></name><name><surname>Keeney</surname><given-names>RE</given-names></name><name><surname>Davis</surname><given-names>LG</given-names></name><etal></etal></person-group><article-title>Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial</article-title><source>J Infect Dis</source><year>1983</year><volume>147</volume><fpage>336</fpage><lpage>340</lpage></citation><citation citation-type="display-unstructured">Reichman RC, Badger GJ, Guinan ME, Nahmias AJ, Keeney RE, Davis LG, et al (1983) Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial. J Infect Dis 147:336–340 <pub-id pub-id-type="pmid">6298318</pub-id></citation></ref><ref id="CR13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reichman</surname><given-names>RC</given-names></name><name><surname>Badger</surname><given-names>GJ</given-names></name><name><surname>Mertz</surname><given-names>GJ</given-names></name><name><surname>Corey</surname><given-names>L</given-names></name><name><surname>Richman</surname><given-names>DD</given-names></name><name><surname>Connor</surname><given-names>JD</given-names></name><etal></etal></person-group><article-title>Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial</article-title><source>JAMA</source><year>1984</year><volume>251</volume><fpage>2103</fpage><lpage>2107</lpage><pub-id pub-id-type="doi">10.1001/jama.251.16.2103</pub-id></citation><citation citation-type="display-unstructured">Reichman RC, Badger GJ, Mertz GJ, Corey L, Richman DD, Connor JD, et al (1984) Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA 251:2103–2107 <pub-id pub-id-type="pmid">6368877</pub-id></citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reitano</surname><given-names>M</given-names></name><name><surname>Tyring</surname><given-names>S</given-names></name><name><surname>Lang</surname><given-names>W</given-names></name><name><surname>Thoming</surname><given-names>C</given-names></name><name><surname>Worm</surname><given-names>AM</given-names></name><name><surname>Borelli</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study</article-title><source>J Infect Dis</source><year>1998</year><volume>178</volume><fpage>603</fpage><lpage>610</lpage></citation><citation citation-type="display-unstructured">Reitano M, Tyring S, Lang W, Thoming C, Worm AM, Borelli S, et al (1998) Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 178:603–610 <pub-id pub-id-type="pmid">9728526</pub-id></citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sacks</surname><given-names>SL</given-names></name><name><surname>Aoki</surname><given-names>FY</given-names></name><name><surname>Diaz-Mitoma</surname><given-names>F</given-names></name><name><surname>Sellors</surname><given-names>J</given-names></name><name><surname>Shafran</surname><given-names>SD</given-names></name></person-group><article-title>Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes</article-title><source>JAMA</source><year>1996</year><volume>276</volume><fpage>44</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1001/jama.276.1.44</pub-id></citation><citation citation-type="display-unstructured">Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD (1996) Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. JAMA 276:44–49 <pub-id pub-id-type="pmid">8667538</pub-id></citation></ref><ref id="CR16"><label>16.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Spruance</surname><given-names>SL</given-names></name><etal></etal></person-group><person-group person-group-type="editor"><name><surname>Sacks</surname><given-names>SL</given-names></name><name><surname>Straus</surname><given-names>SE</given-names></name><name><surname>Whitley</surname><given-names>RJ</given-names></name><etal></etal></person-group><article-title>Herpes simplex labialis</article-title><source>Clinical management of herpes viruses</source><year>1995</year><publisher-loc>Amsterdam</publisher-loc><publisher-name>IOS Press</publisher-name><fpage>3</fpage><lpage>42</lpage></citation><citation citation-type="display-unstructured">Spruance SL (1995) Herpes simplex labialis. In: Sacks SL, Straus SE, Whitley RJ, et al (eds) Clinical management of herpes viruses. IOS Press, Amsterdam, pp 3–42 </citation></ref><ref id="CR17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spruance</surname><given-names>SL</given-names></name><name><surname>Wenerstrom</surname><given-names>G</given-names></name></person-group><article-title>Pathogenesis of recurrent herpes simplex labialis. IV. Maturation of lesions within 8 hours after onset and implications for antiviral treatment</article-title><source>Oral Surg Oral Med Oral Pathol</source><year>1984</year><volume>58</volume><fpage>667</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1016/0030-4220(84)90031-8</pub-id></citation><citation citation-type="display-unstructured">Spruance SL, Wenerstrom G (1984) Pathogenesis of recurrent herpes simplex labialis. IV. Maturation of lesions within 8 hours after onset and implications for antiviral treatment. Oral Surg Oral Med Oral Pathol 58:667–671 <pub-id pub-id-type="pmid">6095159</pub-id></citation></ref><ref id="CR18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tyring</surname><given-names>SK</given-names></name><name><surname>Douglas</surname><given-names>JM</given-names></name><name><surname>Corey</surname><given-names>L</given-names></name><name><surname>Spruance</surname><given-names>SL</given-names></name><name><surname>Esmann</surname><given-names>J</given-names></name></person-group><article-title>A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group</article-title><source>Arch Dermatol</source><year>1998</year><volume>134</volume><fpage>185</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1001/archderm.134.2.185</pub-id></citation><citation citation-type="display-unstructured">Tyring SK, Douglas JM Jr, Corey L, Spruance SL, Esmann J (1998) A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group. Arch Dermatol 134:185–191 <pub-id pub-id-type="pmid">9487210</pub-id></citation></ref><ref id="CR19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wald</surname><given-names>A</given-names></name><name><surname>Carrell</surname><given-names>D</given-names></name><name><surname>Remington</surname><given-names>M</given-names></name><name><surname>Kexel</surname><given-names>E</given-names></name><name><surname>Zeh</surname><given-names>J</given-names></name><name><surname>Corey</surname><given-names>L</given-names></name></person-group><article-title></article-title><source>Clin Infect Dis</source><year>2002</year><volume>34</volume><fpage>944</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1086/339325</pub-id></citation><citation citation-type="display-unstructured">Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L (2002) Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 34:944–948 <pub-id pub-id-type="pmid">11880960</pub-id></citation></ref><ref id="CR20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitley</surname><given-names>RJ</given-names></name><name><surname>Kimberlin</surname><given-names>DW</given-names></name><name><surname>Roizman</surname><given-names>B</given-names></name></person-group><article-title>Herpes simplex viruses</article-title><source>Clin Infect Dis</source><year>1998</year><volume>26</volume><fpage>541</fpage><lpage>555</lpage></citation><citation citation-type="display-unstructured">Whitley RJ, Kimberlin DW, Roizman B (1998) Herpes simplex viruses. Clin Infect Dis 26:541–555 <pub-id pub-id-type="pmid">9524821</pub-id></citation></ref></ref-list></back></article>